In addition, ARID1A-mutant ovarian cancers are sensitive to a combined therapy of exogenous irradiation and PARP inhibition because of a reduced efficiency of the non-homologous end-joining (NHEJ) machinery to repair DNA lesions [120]. This evidence concerns the gene ARID1A and ovarian cancer.